Table 1.
Outcome of randomized trials assessing adjuvant use of carmustine implants or temozolomide compared with control adjuvant radiation arms
| Control arms
|
Control arms (RT)
|
Experimental arms (RT plus BCNU implant or RT and temozolomide)
|
||||||
|---|---|---|---|---|---|---|---|---|
| Study | Number | Median survival (months) | 2-year survival (%) | 3-year survival (%) | Number | Median survival (months) | 2-year survival (%) | 3-year survival (%) |
| Westphal et al (control, placebo wafer, and RT)3,a | 120 (placebo wafer and RT) | 11.6 | 8.3 | 1.7 | 120 (BCNU wafer and RT) | 13.8 | 15.8 | 9 |
| EORTC: (control, RT alone)18,76 | 286 (RT alone) | 12.1 | 10.9 | 4.4 | 287 (RT and TMZ) | 14.6 | 27 | 16 |
| EORTC: biopsy only subgroup | 45 | 7.8 | 4.6 | 4.6 | 48 | 9.4 | 10.4 | 7.8 |
| EORTC: partial resect subgroup | 128 | 11.7 | 9.4 | 3.7 | 126 | 13.5 | 23.7 | 14.3 |
| EORTC: complete resect subgroup | 113 | 14.2 | 15.0 | 5.3 | 113 | 18.8 | 38.4 | 21.4 |
Notes: Copyright ©2012. Dove Medical Press. Reproduced from Kleinberg L. Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide. Core Evid. 2012;7:115–130.16
a
Results based on extent of resection not available for polymer study. Most would have had substantial or total debulking of gross disease based on intraoperative assessment.
Abbreviations: RT, radiotherapy; BCNU, carmustine; EORTC, European Organization for Research and Treatment of Cancer; TMZ, temozolomide; resect, resection.